Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003-06 from the Japan Association of Childhood Leukaemia Study

British Journal of Haematology

Volumn 159, Issue 2, 2012, Pages 204-210

  Imamura, Toshihiko ^a   Iwamoto, Shotaro ^b   Kanai, Rie ^c   Shimada, Akira ^d   Terui, Kiminori ^e   Osugi, Yuko ^f   Kobayashi, Ryoji ^g   Tawa, Akio ^h   Kosaka, Yoshiyuki ⁱ   Kato, Koji ^j   Hori, Hiroki ^b   Horibe, Keizo ^k   Oda, Megumi ^l   Adachi, Souichi ^m  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b MIE UNIVERSITY   (Japan)

^c SHIMANE UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

^e HIROSAKI UNIVERSITY   (Japan)

^f OSAKA CITY GENERAL HOSPITAL   (Japan)

^g SAPPORO HOKUYU HOSPITAL   (Japan)

^h OSAKA NATIONAL HOSPITAL   (Japan)

ⁱ Hyogo Prefectural Children's Hospital   (Japan)

^j JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^k NATIONAL HOSPITAL ORGANIZATION   (Japan)

^l OKAYAMA UNIVERSITY   (Japan)

^m KYOTO UNIVERSITY   (Japan)

more..

Author keywords

Allo HSCT; AML 99; Core binding factor leukaemia; Japan Association of Childhood Leukaemia Study; Paediatric acute myeloid leukaemia

Indexed keywords

ANTHRACYCLINE; CORE BINDING FACTOR; CYTARABINE; ETOPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HUMAN; INFANT; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPRODUCIBILITY; RISK ASSESSMENT; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; JAPAN; LEUKEMIA, MYELOID, ACUTE; MALE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84866858062     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12030     Document Type: Article

References (17)

1. Balgobind, B.V., Hollink, I.H., Arentsen-Peters, S.T., Zimmermann, M., Harbott, J., Beverloo, H.B., von Bergh, A.R., Cloos, J., Kaspers, G.J., de Haas, V., Zemanova, Z., Stary, J., Cayuela, J.M., Baruchel, A., Creutzig, U., Reinhardt, D., Pieters, R., Zwaan, C.M. & van den Heuvel-Eibrink, M.M. (2011) Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica, 96, 1478-1487.
2. Barbaric, D., Alonzo, T.A., Gerbing, R.B., Meshinchi, S., Heerema, N.A., Barnard, D.R., Lange, B.J., Woods, W.G., Arceci, R.J. & Smith, F.O. (2007) Minimally differentiated acute myeloid leukemia (FABAML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. Blood, 109, 2314-2321.
3. Gibson, B.E., Wheatley, K., Hann, I.M., Stevens, R.F., Webb, D., Hills, R.K., De Graaf, S.S. & Harrison, C.J. (2005) Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia, 19, 2130-2138.
4. Gibson, B.E., Webb, D.K., Howman, A.J., De Graff, S.S., Harrison, C.J. & Wheatley, K. (2011) Results of a randomized trial in children with acute myeloid leukaemia: Medical Research Council AML12 trial. British Journal of Haematology, 155, 366-376.
5. Hollink, I.H., Zwaan, C.M., Zimmermann, M., Arentsen-Peters, T.C., Pieters, R., Cloos, J., Kaspers, G.J., de Graaf, S.S., Harbott, J., Creutzig, U., Reinhardt, D., van den Heuvel-Eibrink, M.M. & Thiede, C. (2009) Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia, 23, 262-270.
6. Inaba, H., Rubnitz, J.E., Coustan-Smith, E., Li, L., Furmanski, B.D., Mascara, G.P., Heym, K.M., Christensen, R., Onciu, M., Shurtleff, S.A., Pounds, S.B., Pui, C.H., Ribeiro, R.C., Campana, D. & Baker, S.D. (2011) Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with cloforabine and cytarabine in pediatric relapsed/refractory leukemia. Journal of Clinical Oncology, 29, 3293-3300.
7. Isoyama, K., Oda, M., Kato, K., Nagamura-Inoue, T., Kai, S., Kigasawa, H., Kobayashi, R., Mimaya, J., Inoue, M., Kikuchi, A., Kato, S. & Japan Cord Blood Bank Network. (2010) Long term outcome of cord blood transplantation from unrelated donors as an initial transplantation procedure for children with AML in Japan. Bone Marrow Transplantation, 45, 69-77.
8. Mizushima, Y., Taki, T., Shimada, A., Yui, Y., Hiraumi, Y., Matsubara, H., Watanabe, M., Watanabe, K., Kamitsuji, Y., Hayashi, Y., Tsukimoto, I., Kobayashi, R., Horibe, K., Tawa, A., Nakahata, T. & Adachi, S. (2010) Prognostic significance of the BALLC isoform pattern and CEBPA mutation in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group. International Journal of Hematology, 91, 831-837.
9. Ravandi, F., Cortes, J.E., Jones, D., Faderl, S., Garcia-Manero, G., Konopleva, M.Y., O'Brien, S., Estrov, Z., Borthakur, G., Thomas, D., Pierce, S.R., Brandt, M., Byrd, A., Bekele, B.N., Pratz, K., Luthra, R., Levis, M., Andreeff, M. & Kantarjian, H.M. (2010) Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. Journal of Clinical Oncology, 28, 1856-1862.
10. Rubnitz, J.E., Inaba, H., Dahl, G., Ribeiro, R.C., Bowman, W.P., Taub, J., Pounds, S., Razzouk, B.I., Lacayo, N.J., Cao, X., Meshinchi, S., Degar, B., Airewele, G., Raimondi, S.C., Onciu, M., Coustan-Smith, E., Downing, J.R., Leung, W., Pui, C.H. & Campana, D. (2010) Minimal residual disease-directed therapy for childhood acute myeloid leukemia: results of the AML02 multicenter trial. The Lancet Oncology, 11, 543-552.
11. Sander, A., Zimmermann, M., Dworzak, M., Fleischhack, G., von Neuhoff, C., Reinhardt, D., Kaspers, G.J. & Creutzig, U. (2010) Consequent and intensified relapse therapy improved survival in pediatric AML: result of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia, 24, 1422-1428.
12. Shimada, A., Taki, T., Kubota, C., Tawa, A., Horibe, K., Tsuchida, M., Hanada, R., Tsukimoto, I. & Hayashi, Y. (2007) No nucleophosmin mutations in pediatric acute myeloid leukemia with normal karyotype: a study of the Japanese Childhood AML Cooperative Study Group. Leukemia, 21, 1307.
13. Shimada, A., Taki, T., Tabuchi, K., Taketani, T., Hanada, R., Tawa, A., Tsuchida, M., Horibe, K., Tsukimoto, I. & Hayashi, Y. (2008) Tandem duplications of MLL and Flt3 are cooperated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanease childhood AML cooperative study group. Pediatric Blood & Cancer, 50, 264-269.
14. Silva, F.P.G., Swagemakers, S.M.A., Erpelinck-Verschueren, C., Wouters, B.J., Delwel, R., Vrieling, H., van der Spek, P., Valk, P.J.M. & Giphart-Gassler, M. (2009) Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status. Blood, 114, 3001-3007.
15. Tomizawa, D., Tabuchi, K., Kinoshita, A., Hanada, R., Kigasawa, H., Tsukimoto, I., Tsuchida, M. & Tokyo Children's Cancer Study Group. (2007) Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. Pediatric Blood & Cancer, 49, 127-132.
16. Tsukimoto, I., Tawa, A., Horibe, K., Tabuchi, K., Kigasawa, H., Tsuchida, M., Yabe, H., Nakayama, H., Kudo, K., Kobayashi, R., Hamamoto, K., Imaizumi, M., Morimoto, A., Tsuchiya, S. & Hanada, R. (2009) Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML 99 trial from the Japanese Childhood AML Cooperative Study Group. Journal of Clinical Oncology, 27, 4007-4013.
17. Zwaan, C.M., Meshinchi, S., Radich, J.P., Veerman, A.J., Huismans, D.R., Munske, L., Podleschny, M., Hählen, K., Pieters, R., Zimmermann, M., Reinhardt, D., Harbott, J., Creutzig, U., Kaspers, G.J. & Griesinger, F. (2003) FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood, 102, 2387-2394.